Results 31 to 40 of about 209,106 (262)

Triple-Negative Breast Cancer: A Review of Current Curative Intent Therapies

Current Oncology, 2022
Breast cancer is the most commonly diagnosed malignancy in women, with triple-negative breast cancer (TNBC) accounting for 10–20% of cases. Historically, fewer treatment options have existed for this subtype of breast cancer, with cytotoxic chemotherapy ...
Isaiah MacDonald, Nancy A. Nixon, Omar F. Khan   +2 more
doaj   +1 more source

Neoadjuvant compared to adjuvant chemotherapy combined with trastuzumab in patients with HER2-positive breast cancer: a register-based cohort study

ESMO Real World Data and Digital Oncology
Background: The aim of the study was to compare trastuzumab-based neoadjuvant therapy (NAT) with adjuvant therapy (AT) in a register-based cohort of Swedish patients with primary operable human epidermal growth factor receptor 2 (HER2)-positive breast ...
S. Hosseini-Mellner, Å. Wickberg, E. Olsson, A. Karakatsanis, A. Valachis   +4 more
doaj   +1 more source

Combining Immune-Related Genes For Delineating the Extracellular Matrix and Predicting Hormone Therapy and Neoadjuvant Chemotherapy Benefits In Breast Cancer

Frontiers in Immunology, 2022
Breast cancer (BC) is the most prevalent cancer in women worldwide. A systematic approach to BC treatment, comprising adjuvant and neoadjuvant chemotherapy (NAC), as well as hormone therapy, forms the foundation of the disease’s therapeutic strategy. The
Jianyu Liu, Bo Lei, Xin Yu, Yingpu Li, Yuhan Deng, Guang Yang, Zhigao Li, Tong Liu, Leiguang Ye   +8 more
doaj   +1 more source

Current neoadjuvant treatment options for HER2 positive breast cancer [PDF]

, 2011
Hikmat Abdel-Razeq, Lina MareiSection of Hematology and Medical Oncology, Department of Internal Medicine, King Hussein Cancer Center, Amman, JordanAbstract: Approximately one quarter of patients with breast cancer demonstrate amplification of the human ...
null Marei, Marei L, Abdel-Razeq H, Hikmat Abdel-Razeq   +3 more
core   +1 more source

Evaluation of 192Ir-Based Hypofractionated Stereotactic Ablative Brachytherapy as A Neoadjuvant Treatment for Operable Peripheral Non-small Cell Lung Cancer

Zhongliu Fangzhi Yanjiu, 2019
Objective To evaluate the safety, feasibility and efficacy of template-assisted 192Ir-based hypofractionated stereotactic ablative brachytherapy (SABT) combined with surgery for peripheral non-small cell lung cancer (NSCLC) patients.
SHI Xiangxiang, PANG Haowen, SUN Xiaoyang, REN Peirong, WU Jingbo, LIN Sheng   +5 more
doaj   +1 more source

Solid Pseudopapillary Neoplasm of the Pancreas in Children and Adolescents: Expert Recommendations

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Solid pseudopapillary neoplasm of the pancreas (SPN) is a rare low‐grade malignant exocrine pancreatic tumor, mostly discovered during the second decade of life in females, with a very good prognosis, provided microscopically complete surgical excision is achieved.
Sabine Irtan, Michael Abele, Calogero Virgone, Michaela Kuhlen, Ricardo Lopez‐Almarez, Tal Ben‐Ami, Ewa Bien, Maja Cesen, Malgorzata A. Krawczyk, Andrea Ferrari, Gianni Bisogno, Yves Reguerre, Dominik T. Schneider, Louise Galmiche, Jorg Fuchs, Sarah Braungart, Bilgehan Yalcin, Ines B. Brecht, Daniel Orbach   +18 more
wiley   +1 more source

Neoadjuvant programmed death ligand-1 with chemotherapy versus chemotherapy alone for limited-stage small-cell lung cancer: a retrospective study

Frontiers in Oncology
Summary backgroundOur objective was to investigated the safety and feasibility of neoadjuvant treatment with PD(L)1 inhibitors and chemotherapy followed by surgery for resectable SCLC.MethodsIn this retrospective cohort study, we included patients with ...
Zhi Yang, Yan-qing Wang, Xiujun Chang
doaj   +1 more source

Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer

Frontiers in Immunology, 2022
Immunotherapies, especially the programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) inhibitors, have revolutionized the therapeutic strategies of various cancers. As for colorectal cancer (CRC), the current clinical application of PD-1/PD-
Zhengyang Yang, Guocong Wu, Xiao Zhang, Jiale Gao, Cong Meng, Yishan Liu, Qi Wei, Liting Sun, Pengyu Wei, Zhigang Bai, Hongwei Yao, Zhongtao Zhang   +11 more
doaj   +1 more source

Does neoadjuvant doxorubicin drug-eluting bead transarterial chemoembolization improve survival in patients undergoing liver transplant for hepatocellular carcinoma? [PDF]

, 2017
PURPOSE:We aimed to compare the overall (OS) and disease-free survival (DFS) of patients undergoing orthotopic liver transplant (OLT) for hepatocellular carcinoma who did and did not have neoadjuvant doxorubicin drug-eluting bead transarterial ...
Donal Maguire, Justin Geoghegan, Venkatesha Udupa, Emir Hoti, Jeffrey W. McCann, Dimitri Dorcaratto, Colin P. Cantwell, David P. Brophy, Niamh M. Hogan   +8 more
core   +1 more source

Ovarian Sex Cord Stromal Tumors in Children and Adolescents—The European Standard Clinical Practice Recommendations

Pediatric Blood &Cancer, EarlyView.
ABSTRACT As part of the European Cooperative Study Group for Paediatric Rare Tumours initiative, we developed standard clinical practice guidelines for ovarian sex cord stromal tumors, based on comprehensive national and international cohort analyses, literature review, and a final expert consensus conference.
Dominik T. Schneider, Kris‐Ann Schultz, Nora Schnitzler, Michael Abele, Tal Ben‐Ami, Ewa Bien, Gianni Bisogno, Ines B. Brecht, Maja Cesen, Andrea Ferrari, Michaela Kuhlen, Malgorzata A. Krawczyk, Ricardo Lopez‐Almaraz, Yves Reguerre, Calogero Virgone, Daniel Orbach   +15 more
wiley   +1 more source